Website maintenance took place on Thursday 30 April 2026. If you experience any issues, please contact us.
Notice for Budesonide (Dr Falk Pharma Australia Pty Ltd)
Active ingredients
Budesonide
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
oral suspension
Indication
For the treatment of eosinophilic oesophagitis (EoE)
Therapeutic area
Gastroenterology